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Abstract: Antibodies to oxidized LDL (oxLDL) may be associated with improved outcomes in
cardiovascular disease. However, analysis is restricted by heterogenous study design and endpoints.
Our objective was to conduct a comprehensive systematic review assessing anti-oxLDL antibodies in
relation to coronary artery disease (CAD). Through a systematic literature search, we identified all
studies assessing the relationship of either, IgG or IgM ox-LDL/ copper-oxLDL/ malondialdehyde-LDL,
with coronary atherosclerosis or cardiovascular events in populations with, and without, established
CAD. Systematic review best practices were adhered to and study quality was assessed. An initial
electronic database search identified 2059 records, which was subsequently followed by abstract
and full-text review. Finally, we included 18 studies with over 1811 patients with CAD. The studies
varied according to populations studied, conventional cardiovascular risk factors and interventional
modalities used to assess CAD. IgM anti-oxLDL antibodies were found to indicate protection from
more severe CAD and possibly cardiovascular events, whilst the relationship with IgG is more
complex and difficult to elucidate, with studies reporting divergent results. In this systematic review,
there is evidence that suggests a relationship between anti-oxLDL antibodies and CAD, especially
for the IgM subclass. However, further studies, with well-characterized prospective cohorts, will be
important to clarify these associations.
Keywords: myocardial infarction; inflammation; antibody; coronary angiography; coronary
artery disease
1. Introduction
Cardiovascular disease (CVD) remains the leading cause of death worldwide for the last 15 years [1],
despite significant pharmaceutical and technological advancements. There is, therefore, a clear mandate
for better, and earlier, identification of patients at risk, as well as improved management of CVD when it
occurs. Oxidized low density lipoprotein (oxLDL) is thought to be central to the atherosclerotic cascade,
the common denominator in the pathophysiology of major adverse cardiovascular and cerebral events.
OxLDL acts as an antigen, which is recognised by macrophages and induces foam cell formation, with
ensuing plaque lipid core development, apoptosis, cell death, and cytokine production [2]. OxLDL
is formed through the post-translational oxidative modification of LDL that has crossed the intimal
arterial layer, becoming trapped beneath it in the sub-intimal space. OxLDL is actually a collective term,
reflecting a wide variety of oxidative changes to the LDL particle, including aldehyde adduction, such
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as malondialdehyde (MDA) onto Apolipoprotein B, the principle protein of LDL. Notably, post mortem
studies have suggested that lesions with greater oxLDL deposition may be at increased risk of plaque
rupture [3,4]. Therefore, oxLDL is an ideal target for the investigation of potential identification of
atherosclerotic plaques prone to rupture. Moreover, multiple studies have demonstrated that elevated
levels of serum oxLDL are associated with the development of future CVD and often poorer prognosis,
with conceivable clinical use as a biomarker [5–12].
Moving on from the measurement of oxLDL, the measurement of autoantibodies to oxLDL may
allow improved cardiovascular risk stratification. Auto-antibodies may be generated for any of the
oxidation specific epitopes that have been developed for the oxidative modification of LDL. Many
studies have been performed to explore the association between autoantibodies to oxLDL and CVD.
However, it is somewhat difficult to draw clear conclusions, given the contradictory findings, variable
study design with dissimilar endpoints, as well as different laboratory assays and techniques.
This systematic review aims to evaluate the studies that have been performed to assess the
association between autoantibodies to oxLDL and cardiovascular mortality. There are autoantibodies to
a wide variety of oxidation specific epitopes that have been evaluated in the literature, but this systematic
review focuses on MDA-LDL, copper-oxidized LDL (Cu-oxLDL), and oxLDL (with non-specified
oxidative-modified epitopes on LDL), the most widely reported autoantibodies. Additionally, given
the contrasting endpoints used and the broad clinical spectrum covered by CVD, this review focuses
on CAD with cardiac endpoints, including CAD severity as assessed at coronary angiography (CAG).
2. Materials and Methods
2.1. Search Strategy
In June 2018 we systematically searched Medline, Embase, Web of Science and Google Scholar
electronic databases for relevant literature using different variations, abbreviations and language
variations of the following keywords: oxidized low-density lipoprotein, antibodies, autoantibodies,
atherosclerosis, and coronary artery disease (detailed search strategy given in Supplementary File S1).
In addition, we hand-searched the reference lists of relevant reviews in the field for the identification
of additional publications for inclusion. Our search was limited to peer-reviewed articles that have
been published in English and that carried out studies on human adults. In addition, the studies had
to focus on healthy individuals or patients with CAD. Studies that centred primarily on patients with
autoimmune diseases, for example Systemic Lupus Erythematosus, were excluded.
2.2. Review Method and Selection Criteria
Studies were eligible in the study, either, if they reported an association between IgG and/or
IgM autoantibodies to MDA-LDL, Cu-oxLDL, or a total oxLDL and the occurrence of cardiovascular
events during a follow-up of at least one year; or if they reported an association between IgG
and/or IgM autoantibodies to MDA-LDL, Cu-oxLDL, or total oxLDL with degree of coronary
atherosclerosis assessed by coronary angiography or other coronary imaging modality. We excluded
cross-sectional studies that focused on differences in serum levels of MDA-LDL, Cu-oxLDL, or total
oxLDL autoantibodies between patients with different types of CAD (myocardial infarction (MI),
unstable angina, stable angina or prior MI), as the degree of CAD cannot be quantified using these
definitions. In addition, studies were excluded that did not specify which subclass of autoantibody
were evaluated (i.e., total versus IgG versus IgM), so as to permit analysis per immunoglobulin (Ig)
subtype, given the diverging associations with CVD reported in the literature.
Two physician reviewers (VJB and MMV) independently screened the publications for eligibility at
title or abstract level. The remaining publications underwent full text review. The differences between
reviewers regarding study selection were resolved by a third reviewer (RK). To assess the quality of
the included studies, we used the Newcastle-Ottawa Scale for cohort studies and case-control studies.
A modified scale was used for cross-sectional studies [13].
Antioxidants 2019, 8, 484 3 of 17
2.3. Data Extraction
For each included study, data was extracted independently by two reviewers (VJB and MMV).
Subsequently, the information was compared and merged, and discrepancies were resolved by
consensus. The extracted data consisted of study and patient characteristics, autoantibodies of interest,
method for determining the antibody levels, and the association between the antibody levels and the
clinical events or degree of CAD, as quantified by imaging. If the studies used uni- and multi-variable
models to assess these associations, we chose to include the results of the multivariable model adjusted
for the most confounders.
3. Results
The systematic literature search yielded a total of 2059 records, potentially eligible for our current
analysis. Based on the titles and abstract, 1988 records were excluded, hence 71 studies underwent
full text review. Subsequently, 53 studies were further excluded, as they did not meet the inclusion
criteria. 18 original studies were included in the systematic review (Figure 1). The study populations
and the baseline characteristics of the included studies are shown in Table 1. The results of the quality
assessments for all studies are provided in Table S1.
Figure 1. Flow diagram.
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Table 1. Baseline characteristics of the included studies.
Author Year Population (n) InvestigatedBiomarkers Sample Size Age in Years Mean (SD) Male Gender (%) DM (%) HTN (%)
Current
Smoking (%)
CAD noCAD CAD no CAD CAD
no
CAD CAD
no
CAD CAD
no
CAD CAD
no
CAD
Cohort studies
Björkbacka [14] 2016
Population-based
prospective
cohort (5393)
anti-p45 IgG,
anti-p45 IgM,
anti-p210 IgG,
anti-p210 IgM
398 4995
61.1
[57.2–64.7]
*
57.6
[52.2–62.5]
*
61.6 39.8 19.8 7.4 81.2 62.5 33.8 26.1
Maiolino [15] 2012 CAG patients(733) b
IgG
anti-MDA-LDL 733 63.3 78.4 NR NR 7.3
Meeuwsen [16] 2017
168
endarterectomy
patients
IgG
anti-oxLDL,
IgM
anti-oxLDL
168 70.1 (9.6) 62.8 23.8 86.6 35.7
Prasad [17] 2017
Population-based
prospective
cohort (3509)
IgG
anti-MDA-LDL,
IgM
anti-MDA-LDL
190 2914 43.7 (10.1) † 44.1† 11.6† 34.4† 29.3†
Tsimikas [18] 2007 CAG patients(504) a
IgG
anti-MDA-LDL,
IgM
anti-MDA-LDL
504 60.1 61.7 NR 46.0 7.9
Tsimikas [10] 2012
Population-based
prospective
cohort (765)
IgG
anti-cu-oxLDL,
IgM
anti-MDA-LDL
138 627 68.8 (10.5) 61.4 (10.9) 48.5 59.4 13.8 6.9 75.4 66.0 17.4 20.4
Wilson [19] 2006
Population-based
prospective
cohort (2619)
IgG
anti-MDA-LDL 151 2468 49.52 † NR NR NR NR NR NR NR NR
Case-control studies
Khamisc [20] 2016
Hypertensive
patients
receiving blood
pressure-lowering
treatment (1852)
IgG
anti-MDA-LDL,
IgM
anti-MDA-LDL
485 1367 65.3 (7.8) 65.3 (7.6) 84.5 84.9 30.9 26.3 NR NR 7.8 7.6
Ravandi [21] 2011
Population-based
prospective
cohort (2471)
IgG
anti-MDA-LDL,
IgM
anti-MDA-LDL
748 1723 65.4 (7.8) 65.4 (7.8) 62.8 61.6 NR NR NR NR 15.5 8.6
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Table 1. Cont.
Author Year Population (n) InvestigatedBiomarkers Sample Size Age in Years Mean (SD) Male Gender (%) DM (%) HTN (%)
Current
Smoking (%)
CAD noCAD CAD no CAD CAD
no
CAD CAD
no
CAD CAD
no
CAD CAD
no
CAD
van den Berg d [22] 2018
87 subjects with
CHD, 227
subjects free of
CHD
IgG
anti-MDA-LDL,
IgM
anti-MDA-LDL
87 227 60.4 (6.3) 59.8 (6.4) 67.8 64.8 14.9 7.9 100 100 8 6.6
Cross-sectional studies
Bilgen [23] 2005
CAD patients
(136). healthy
controls (31)
IgG
anti-oxLDL 136 31 57.6 (11.3) 53.5 (10.2) 70.5 67.8 13.2 0 30.9 0 47.8 0
Che [24] 2011 CAG patients(154)
IgG
anti-oxLDL 117 37 63.7 (10.6) 62.0 (11.5) 63.4 64.9 24.8 16.2 64.1 70.3 43.6 24.3
Chen [25] 2011 CAG patients(558)
IgG
anti-MDA-LDL,
IgM
anti-MDA-LDL
334 224 60.7 53.2 0 0 31.4 17.9 63.2 47.3 21.3 16.5
Garrido-Sanchez
[26] 2009
CAG patients
(236)
IgG
anti-oxLDL,
IgM
anti-oxLDL
NR NR NR NR NR NR NR NR NR NR NR NR
Gruzdeva [27] 2014
STEMI patients
(400), 33 healthy
controls
IgG
anti-oxLDL 400 NR 60.3 (1.1) NR 67.5 NR NR NR 69.8 NR 42 NR
Maiolino [15] 2012 CAG patients(733) b
IgG
anti-MDA-LDL 733 63.3 78.4 NR NR 7.3
Moohebati [28] 2013
CAG patients
(63), healthy
controls (24)
IgG
anti-oxLDL 31 56 59.4 (10.1) 58.3 38.7 58.9 41.9 10.7 64.5 44.6 51.6 25
Rossi [29] 2003 CAG patients(529)
IgG
anti-MDA-LDL 445 84 63 62 NR NR NR NR NR NR NR NR
Soto [30] 2009
CAG patients
(20), healthy
controls (10)
IgG
anti-oxLDL,
IgM
anti-oxLDL
13 17 59 36.5 100 52.9 23.1 0 69.2 11.8 46.2 11.8
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Table 1. Cont.
Author Year Population (n) InvestigatedBiomarkers Sample Size Age in Years Mean (SD) Male Gender (%) DM (%) HTN (%)
Current
Smoking (%)
CAD noCAD CAD no CAD CAD
no
CAD CAD
no
CAD CAD
no
CAD CAD
no
CAD
Tsimikas [18] 2007 CAG patients(504) a
IgG
anti-MDA-LDL,
IgM
anti-MDA-LDL
504 60.1 61.7 NR 46.0 7.9
van den Berg d [22] 2018
87 subjects with
CHD, 227
subjects free of
CHD
IgG
anti-MDA-LDL,
IgM
anti-MDA-LDL
87 227 60.4 (6.3) 59.8 (6.4) 67.8 64.8 14.9 7.9 100 100 8 6.6
If CAG patients were classified as having normal coronary arteries, their baseline characteristics are mentioned under ‘without CAD’ and combined with healthy controls, if needed. Note
that experimental biomarker assays are methodologically heterogenous. Please refer to the original publications for assay details. a: all patients were divided into either 2 groups; one with
at least one stenosis with a diameter > 50% and one group without. As for the latter group, we cannot determine the baseline characteristics for the patients without any CAD. We chose to
summarize all the baseline characteristics under known CAD. b: of which 570 used for analysis. c: Case-control constructed from participants of a randomized controlled trial comparing
two blood pressure lowering regimes: (1) a beta-blocker with a thiazide diuretic and a (2) dihydropyridine calcium channel blocker with an angiotensin-converting enzyme inhibitor. d:
two separate cohorts are discussed in this paper, both are included separately in the systematic review. * median [IQR]. † Baseline characteristics only available for the entire group. CAD:
coronary artery disease, CAG: coronary angiography, DM: diabetes mellitus, HTN: hypertension, MI: myocardial infarction, NR: not reported; SD: standard deviation.
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3.1. Autoantibodies against oxLDL and Severity of CAD
A total of 11 cross-sectional studies were identified that explored the association between the
degree of CAD, as quantified by CAG, intravascular ultrasound (IVUS) or near-infrared spectroscopy
(NIRS) and IgG oxLDL autoantibodies [15,18,22–30], whilst five studies evaluated the relationship
with IgM oxLDL autoantibodies [18,22,25,26,30]. Nine of these studies investigated all consecutive
patients undergoing clinically indicated CAG [15,18,22–24,26,28–30], one study included only women
undergoing CAG [25], and one study included solely patients with ST-segment elevation MI
(STEMI) [27]. The endpoints were defined as number of diseased coronary arteries [18,23,26,27,29];
the Gensini score [24]; the Duke score [15] (both being composite scores for CAD lesion location and
severity); a custom angiographic severity score [25]; or plaque characteristics determined by IVUS and
lipid core burden index (LCBI) measured by NIRS, both measured in a non-culprit vessel [22]. Two
studies divided their CAG patients in groups with at least one stenosis >50% and a group without
stenosis >50%, and compared these two groups with healthy individuals [28,30]. An overview of the
study results is described in Table 2.
Except for Che et al. [24] and Gruzdeva et al. [27], nine studies described a non-significant
association between IgG anti-oxLDL antibodies or anti-MDA-LDL antibodies and the severity of CAD,
as quantified at CAG [15,18,22,23,25,26,28–30]. Che et al. [24] found a negative association between
the natural logarithm of the (Gensini-score + 1) and serum IgG anti-oxLDL autoantibodies in 154
consecutive CAG patients. However, their findings seem to be heavily (negatively) biased by an
outlying value of IgG and were not confirmed in multivariable analysis. In contrast to Che et al.,
Gruzdeva et al. [27] reported a positive association between IgG anti-oxLDL antibodies and the number
of coronary arteries with a stenosis of >75% in patients undergoing CAG for STEMI. In a univariable
logistic regression model, with the dependent variable of one-vessel disease versus multi-vessel disease,
IgG autoantibodies to oxLDL had a discriminative ability, expressed by a c-statistic of 0.85.
The association between IgM anti-MDA-LDL or total anti-oxLDL antibodies has been investigated
less extensively. In the study by Garrido-Sanchez et al. [26], an inverse relationship between IgM
anti-ox-LDL levels and the number of diseased coronary arteries was found (p < 0.005). The same
association was reported by Tsimikas et al. [18] for both IgM anti-MDA-LDL (p = 0.027) and IgM
anti-Cu-oxLDL (p = 0.030). However, in a multivariable logistic regression model with the presence of
obstructive CAD (defined as 1 or more stenosis of >50%) as the dependent variable, IgM anti-oxLDL
level was not an independent predictor of obstructive CAD. Similarly, van den Berg et al. [22] reported
that plaque burden or volume in a non-culprit vessel, as determined by IVUS measurements, was not
significantly associated with IgM anti-oxLDL. In contrast, IgM anti-oxLDL was inversely associated
with the degree of necrotic core in the same lesion and with the lipid core burden index (LCBI)-score of
the worst 4mm in the measured segment [22]. The study by Chen et al. [25] also revealed that, higher
IgM antibodies levels were associated with less severe CAD. In this study, patients with no, to very,
mild (<20% stenosis) CAD had significantly higher IgM levels than patients with at least one stenosis
of >20%, after adjusting for the effects of age, smoking, total cholesterol, and LDL cholesterol. This
inverse relationship seemed to be more profound in Caucasian women than in Afro-American women.
However, when IgM anti-oxLDL serum levels were correlated with a custom-made CAD severity
score that accounted for severity of stenosis, adjusted for collaterals and lesion location, no significant
association was found. Finally, although, the study by Soto et al. [30] did find higher IgM anti-oxLDL
antibody levels in healthy controls and patients, without significant CAD, as quantified by CAG than
in patients with CAD, these results should be interpreted with caution given only 30 patients were
analysed (20 CAG patients and 10 controls).
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Table 2. Relationship between anti-oxidized low density lipoprotein (anti-oxLDL) antibodies and coronary artery disease assessed by coronary imaging.
Author Index Group (n) Reference Group (n) Statistical Method
Confounders
Adjusted for in
Statistical Analysis
Outcome IgG Anti-oxLDL IgM Anti-oxLDL
Bilgen [23] CAG patients (136) Healthy controls (36) ANOVA withpost-hoc Tukey Diseased coronary arteries (n) NS
Che [24] CAG patients (154) Multiple linearstepwise regression
hs-CRP, fasting
glucose, serum
albumin
ln(Gensini score + 1)
Beta
−0.020
(−0.033,
−0.006)
Chen [25] Female CAGpatients (558) ANOVA
Age, smoking, and
total and LDL
cholesterol
<20% stenosis vs >20% stenosis NS ↓
Garrido-Sanchez [26] CAG patiens (236) NR Diseased coronary arteries (n) NS ↓
Gruzdeva [27] STEMI patients(400) Healthy controls (33)
Kruskal-Wallis,
followed by
Mann-Whitney with
Bonferonni correction
Diseased coronary arteries
(>75%) (n) ↑
Maiolino [15] CAG patients (733) ANOVA Duke CAD score NS
Moohebati [28] CAG patients (63) Healthy controls (24) ANOVA 1 or more stenosis (>50%) vs nostenosis vs healthy control NS
Rossi [29] CAG patients (529) ANOVA Diseased coronary arteries(>50%) (n) NS
Soto [30] CAG patients (20) Healthy controls (10) ANOVA 1 or more stenosis (>50%) vs nostenosis vs healthy control unclear ↓
Tsimikas [18] CAG patients (504) Logistic regression
Age, gender, LDL-C,
smoking, HDL,
hypertension
obstructive CAD (>50%) vs no
obstructive CAD NS, OR not given NS, OR not given
van den Berg [22] CAG patients (143)
Linear regression,
trend test among four
quartiles
Age, gender, diabetes,
smoking, previous
statin use, LDL and
HDL cholesterol
IVUS determined plaque
characteristics in a non-culprit
vessel, NIRS determined LCBI
score in a non-culprit vessel
NS ↓
↑ Indicates a significantly positive association with outcome (high Ig-levels are associated with more CAD), ↓ Indicates a significantly inverse association with outcome (high Ig-levels are
associated with less CAD). CAD: coronary artery disease, CAG: coronary angiography, hs-CRP: high-sensitive C-reactive protein, Ig: immunoglobulin, Ig: immunoglobulin, NR: not
reported, NS: Not significant, OxLDL: oxidized LDL, STEMI: ST-elevation myocardial infarction.
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3.2. Autoantibodies against oxLDL and Cardiovascular Events in Patients without Established CAD
We found four cohorts [10,14,17,19] and three nested case-control studies [20–22] that assessed
the association between IgG and IgM anti-oxLDL and cardiovascular events in subjects without
established CAD. There was significant variation in the frequency of cardiovascular risk factors present
amongst the population-based studies. For example, Khamis et al. and Van den Berg et al. conducted
their studies in subjects with hypertension [20,22]. Study populations generally consisted mainly of
Caucasians. Whereas, Prasad et al. included subjects differing in ethnicity (Caucasian, Black and
Hispanic) [17]. All seven studies quantified autoantibodies in blood samples collected at baseline and
assessed long-term cardiovascular outcomes. Björkbacka et al. additionally distinguished between
IgM and IgG autoantibodies against amino acid sequences 661–680 (p45) and 3136–3155 (p210) [14].
All seven studies assessed the association between IgG oxLDL autoantibodies and cardiovascular
end points (Table 3). Both Tsimikas et al. and Prasad et al. found that elevated levels of IgG anti-oxLDL
were associated with a greater risk of developing future events (hazard ratio (HR) per standard
deviation (SD) increase: 1.18, 95% confidence interval (CI) 1.03–1.37, and HR for fourth quartile
vs first quartile: 1.97, 95%CI 1.30–2.99, respectively) [10,17]. Conversely, Khamis et al. found a
protective association between IgG anti-oxLDL and cardiovascular end points, with cases having
lower levels of IgG anti-oxLDL than controls (Odds ratio (OR) for third versus first tertile: 0.74, 95%CI
0.56–0.97) [20]. The remaining four studies that assessed the association between IgG anti-oxLDL
levels and cardiovascular end-points did not detect significant associations.
Six studies assessed the association between IgM anti-oxLDL levels and cardiovascular end-points
(Table 3). Tsimikas et al. found that higher serum levels of IgM oxLDL autoantibodies were associated
with a lower risk of developing cardiovascular end points (HR/SD increase: 0.69, 95%CI 0.50–0.95) [10].
Van den Berg et al. also indicated a strong protective effect of IgM anti-MDA-LDL antibodies on future
CAD events (OR of third versus first tertile 0.29 (0.11, 0.76; p = 0.012; p = 0.016 for trend) [22]. A
similar protective association was seen in the study by Björkbacka et al. for IgM-p45 autoantibodies,
with an adjusted HR for third vs first tertile of 0.59 (95%CI: 0.46–0.76; p < 0.001). No significant
association between IgM-p210 autoantibodies and cardiovascular end points was observed [14]. The
remaining three studies did not find a significant association between IgM anti-MDA-LDL antibodies
and events [17,20,21].
Antioxidants 2019, 8, 484 10 of 17
Table 3. Anti-oxLDL antibodies and cardiac endpoints in subjects without prevalent coronary artery disease.
Author Study Follow-upPeriod, Years
Statistical
Method
Matching
Variables
Confounders
Adjusted for in
Statistical Analysis
Endpoint IgG Anti-oxLDL IgM Anti-oxLDL
Björkbacka [14] Cohortstudy >15
Multivariable
Cox regression
Age, gender, LDL,
HDL, SBP,
triglycerides, hs-CRP,
smoking,
anti-hypertensive
treatment, diabetes
Fatal and non-fatal MI,
ischemic heart disease
Adjusted HR between tertiles:
IgG anti-MDA-LDL p45: 1.00
vs 0.85 (0.66–1.11) vs 0.89
(0.68–1.16) p trend:0.89; IgG
anti-MDA-LDL p210: 1.00 vs
0.81 (0.63–1.06) vs 0.96
(0.74–1.23) p trend: 0.29
Adjusted HR between tertiles:
IgM anti-MDA-LDL p45: 1.00
vs 0.79 (0.t62–0.99) vs 0.59
(0.46–0.76) p trend: 0.001; IgM
anti-MDA-LDL p210: 1.00 vs
0.81 (0.63–1.06) vs 0.96
(0.74–1.23) p trend: 0.29
Khamis [20]
Nested
case-control
study
5.5 (median)
Conditional
logistic
regression
Age, Gender
Smoking, diabetes,
SBP, total cholesterol,
HDL, creatinine, BMI,
family history of
CAD,
anti-hypertensive and
statin treatment, CRP,
NTproBNP
Fatal coronary heart
disease, symptomatic
non-fatal MI, coronary
revascularization, fatal
and non-fatal stroke
Adjusted OR per SD increase:
IgG anti-MDA-LDL 0.83
(0.72–0.95)
Adjusted OR per SD increase:
IgM anti-MDA-LDL 0.90
(0.78–1.03)
Prasad [17] Cohortstudy 10.5 (median)
Multivariabel
Cox regression
Age, gender,
hypertension,
diabetes, smoking,
BMI, LDL, HDL,
triglycerides,
ethnicity
Cardiac death, non-fatal
MI, stroke/TIA, unstable
angina requiring
hospitalization and
arterial vascularization
that included CABG, PCI,
carotid endarterectomy,
carotid stenting and
peripheral artery
revascularization
Adjusted HR 4th quartile vs
first quartile: IgG
anti-MDA-LDL: 1.97
(1.30–2.99)
Adjusted HR 4th quartile vs
first quartile: IgM
anti-MDA-LDL: 0.96
(0.63–1.45)
Ravandi [21]
Nested
case-control
study
6 (mean)
Conditional
logistic
regression
Age, gender,
time of
enrollment
Diabetes, smoking,
SBP, LDL, HDL
cardiac death, hospital
admission with CAD
Adjusted OR between tertiles:
IgG anti-MDA-LDL 1.00 vs
0.80 (0.64–1.00) vs 0.94
(0.75–1.18), ptrend: 0.4
Adjusted OR between tertiles:
IgM anti-MDA-LDL: 1.00 vs
1.01 (0.81–1.26) vs 0.91
(0.72–1.15), p trend: 0.6
Tsimikas [10] Cohortstudy > 15
Multivariabel
Cox regression
Age, Gender,
previous CVD, SBP,
smoking, diabetes,
ferritin, LDL, HDL,
alcohol consumption,
social status, sport
activity, CRP
Stroke, MI, new-onset
unstable angina, acute
coronary interventions
and cardiac death
Adjusted HR: IgG
anti-cu-oxLDL: 1.18 (1.03–1.37)
Adjusted HR: IgM
anti-MDA-LDL: 0.69
(0.50–0.95)
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Table 3. Cont.
Author Study Follow-upPeriod, Years
Statistical
Method
Matching
Variables
Confounders
Adjusted for in
Statistical Analysis
Endpoint IgG Anti-oxLDL IgM Anti-oxLDL
Van den Berg
[22]
Nested
case-control
study
4.5 (mean)
Conditional
logistic
regression
Age, gender,
time of
enrollment
Smoking, diabetes,
baseline HDL, blood
pressure treatments,
either total IgG or
total IgM.
fatal MI, non-fatal MI
Q-wave criterium,
non-fatal MI T-wave
criterium, sudden death,
new-onset ischemic heart
disease or new-onset
congestive heart failure
Adjusted OR between tertiles
per SD increase in loge IgG
anti-MDA-LDL: 1.00 vs
0.65(0.33–1.28) vs 0.93
(0.45–1.92) ptrend: 0.82
Adjusted OR between tertiles
per SD increase in loge IgM
anti-MDA-LDL: 1.00 vs 0.90
(0.45–1.80) vs 0.29 (0.11–0.76)
ptrend: 0.016
Wilson [19] Cohortstudy > 8
Multivariabel
Cox regression
Age, total cholesterol,
HDL, smoking, SBP
Angina pectoris, unstable
anginga pectoris, MI,
cardiac death, TIA and
stroke
Adjusted HR males and
females per 1000 units: IgG
anti-MDA-LDL: 1.00 (1-1); IgG
anti-MDA-LDL: 1.00 (1-1)
Legend: HR: hazard ratio, Ig: immunoglobulin, LDL: low density lipoprotein, MDA: malondiadehyde, OR: odds ratio, SD: standard deviation.
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3.3. Autoantibodies against oxLDL and Cardiovascular Events in Patients with Established CAD
Only two studies investigated the prognostic value of autoantibodies to oxLDL in CAD patients; one
additional study was identified that included patients with known CVD (summarised in Table 4). The
two CAD studies included (mainly Caucasian) patients undergoing clinically indicated CAG [15,18],
and the CVD study included patients undergoing carotid endarterectomy [16]. Antibody levels,
determined from baseline samples and taken prior to intervention, were evaluated with events during
follow-up. Among 168 patients undergoing carotid endarterectomy, Meeuwsen et al. [16] did not find
any significant differences in baseline IgG and IgM anti-oxLDL in patients by whom the endpoint, a
composite of cardiac death, non-fatal MI, stroke, and percutaneous or peripheral intervention, later
occurred and in whom it did not occur. Similar to the study by Meeuwsen et al., Tsimikas et al. reported
no significant associations between both IgG and IgM anti-MDA-LDL levels of 504 patients included
in the BRUNECK study and cardiovascular events during a median follow-up of 4 years. However,
during CAG, only 271 patients had obstructive CAD, the number of events (44; 20 all-cause deaths,
14 MIs, and 10 strokes) was low and the paper does not mention the statistical techniques used for
analysis. On the contrary, Maiolino et al. [15] reported different results in patients undergoing clinically
indicated CAG. In blood samples of 544 patients from the GENICA (Genetic and ENvironmental
factors in Coronary Atherosclerosis) study, there was a significant positive association between IgG
anti-MDA-LDL levels and both, the occurrence of cardiovascular death (p = 0.04), and the occurrence
of cardiovascular events (p = 0.005). In an additional analysis, 136 of the 140 patients from the highest
IgG anti-MDA-LDL quartile were successfully matched to 136 patients from the other three quartiles,
based on a propensity score that was computed with the most well-identified clinical characteristics
associated with cardiovascular events. When comparing patients with high oxLDL antibody levels
with their propensity matched controls, the patients with high levels had significantly less chance
of cardiovascular death-free survival (83.1% vs 89.0%, p = 0.025) and less chance of cardiovascular
event-free survival (69.2% versus 77.7%, p = 0.030), during a median follow-up of 7.2 years.
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Table 4. Anti-oxLDL antibodies and cardiac endpoints in subjects undergoing clinically indicated coronary angiography (CAG).
Author Index Group(n) Reference Group (n)
Follow-up
Period, Years
Statistical
Method Matching Variables
Confounders
Adjusted for
in Statistical
Analysis
Outcome IgGAnti-oxLDL
IgM
Anti-oxLDL
Maiolino [15]
CAG patients
from highest
IgG
anti-MDA-LDL
quartile (136)
CAG patients from the
lower three IgG
anti-MDA-LDL
quartiles matched
based on propensity
score
7.2 (median) Kaplan-Meier
Gender, Age, BMI, LDL- and
HDL-cholesterol, triglycerides,
serum creatinine, homocysteine,
glycemia, serum sodium
concentration, heart rate arterial
hypertension, smoking habit,
LVEF, the Duke Prognostic Index
of coronary athersosclerotic
burden, length of follow-up,
history and treatment variables
Cardiac death, composite
of non-fatal MI, non-fatal
stroke, and cardiac death
Event-free
survival;
1-3rd Q vs.
4th Q:
77.7% vs.
69.2%
Meeuwsen [16]
Carotid
endarterectomy
patients (168)
3 Coxregression
Composite of cardiac death,
stroke, non-fatal MI,
coronary intervention, and
peripheral intervention
(including amputation)
HR 1.01
(0.98–1.03)
Tsimikas [18] CAG patients(504) 4 (median) NR
Composite of non-fatal MI,
non-fatal stroke, and
cardiac death
NS NS
↑ Indicates a significantly higher level in the index group compared with the reference group, ↓ Indicates a significantly higher level in the index group compared with the reference group.
BMI: body mass index, CAG: coronary angiography, HDL: high density lipoprotein, Ig: immunoglobulin, LDL: low density lipoprotein, LVEF: left ventricular ejection fraction, NR: not
reported, NS: not significant, MDA: malondiadehyde, MI: myocardial infarction, oxLDL: oxidized LDL.
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4. Discussion
This systematic review highlights that the results on associations between anti-oxLDL antibodies
and cardiovascular endpoints, described in the literature so far, are heterogeneous and several aspects
remain inconclusive. Moreover, despite a comprehensive search methodology, only 18 original studies
were identified that satisfied the broad inclusion/exclusion criteria. The studies identified were
generally of a very high standard, as assessed by the (modified) Newcastle-Ottawa Scale, except for low
scores reported for some of the cross-sectional studies (Supplementary Table S1). All of the included
studies reported on IgG anti-oxLDL antibodies, with a smaller proportion reporting associations with
IgM anti-oxLDL antibodies.
The studies investigating the relationship between anti-oxLDL antibodies and CAD as quantified
by CAG (Table 2) varied in inclusion criteria and endpoint definition, and were often characterized
by methodologically weak designs (Table S1). Given the currently available evidence, there is little
to support the hypothesis that IgG anti-oxLDL antibodies and CAD severity are related, except for
perhaps in STEMI patients. IgM antibodies against oxLDL seem to have an inverse relationship with
the CAD severity. However, it is unclear if this relationship is also as strongly apparent when adjusted
for confounders. It is important to note that all the studies evaluating IgM also assessed IgG anti-oxLDL
antibodies, yet no relationship is found with IgG. Conversely, a clear association is found with IgM
anti-oxLDL antibodies in the same study populations. This further strengthens the lack of an identified
relationship between IgG anti-oxLDL antibodies and CAD.
The inverse relationship between IgM antibodies and the necrotic core volume/ LCBI score, as
demonstrated by van den Berg et al. [22], is provoking and promising, as both endpoints have been
shown previously to correlate with future cardiovascular events [31]. Future studies should use a
well-validated score for CAD severity, use a regression analysis to establish the relationship between
this (semi-) continuous endpoint and antibodies, as well as perform multivariable adjustments in
order to confirm this relationship. In addition, there should be sufficient patients included to perform
sub-group analysis, based on CAG indication (e.g., STEMI, non-STEMI, stable CAD).
The seven studies (Table 3) conducted to assess the association of anti-oxLDL antibodies with
cardiovascular endpoints in patients without objectified CAD, demonstrated inconclusive conclusions
with IgG anti-oxLDL antibody levels. Conversely, it seems that IgM anti-oxLDL levels are inversely
associated with the events. Moreover, the divergent results of the studies investigating cardiovascular
endpoints with anti-oxLDL antibodies, in patients undergoing clinically indicated CAG (Table 4), may be
partially explained by differences in design, statistical analysis, and number of events occurring. Current
studies reported mixed endpoints, vastly different endpoints between studies, and the use of different
experimental techniques or antibodies. Well-designed prospective studies, with well-characterised
populations, amongst diagnosed CAD patients or at-risk populations, will be needed for further
investigations if anti-oxLDL antibody levels are indeed associated with cardiovascular events. It may
also be prudent to focus on coronary heart disease endpoints (i.e., non-fatal MI or cardiac death) as
these are objective endpoints with more diagnostic certainty than their vascular or cerebrovascular
counterparts. Naturally, this will require greater patient recruitment due to lower event rates; but
may serve to more confidently assess potential associations. Another confounder to consider is the
interaction of cardiovascular preventative medications. Statins have been demonstrated to somewhat
counter-intuitively reduce IgM and increase IgG anti-MDA-LDL antibody levels, independent of
dose [32]. Whereas, in the SARD (Standard versus high-dose therApy with Rosuvastatin for lipiD
lowering) randomised clinical trial, rosuvastatin reduced total oxLDL levels in a dose-dependent
manner. Thus, the interaction of statins with oxLDL is also complex and requires further clarification.
Despite the differences in study design and the presence of confounders discussed above, it
appears that IgM anti-oxLDL antibodies indicate protection from CV events and more severe CAD,
whilst the relationship with IgG is more complex and difficult to elucidate. The biological role of
these autoantibodies needs to be considered, more than just in their putative role as biomarkers in
clinical practice. It is hypothesised that, as a key component of the innate immune system, IgM
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anti-oxLDL antibodies perform homeostatic functions, maintaining the equilibrium of atherosclerosis
development. Perhaps in the presence of overwhelming stimuli, such as traditional cardiovascular risk
factors or other inflammatory triggers, a mal-adaptive immune response occurs, with immunoglobulin
class switching to IgG and accelerated atheroma deposition/plaque rupture [2]. Interestingly, a
recent set of experiments using a single-chain variable fragment of E06, a naturally occurring IgM
antibody that inhibits the uptake of oxLDL into macrophages, has demonstrated reduced levels of
atheroma development, systemic inflammation, and even prolonged life in LDL-receptor-null mice fed
a high-cholesterol diet [33]. Thus, this study provides plausible mechanistic evidence for the theorised
beneficial anti-inflammatory and anti-atherosclerotic actions of IgM anti-oxLDL antibodies.
Limitations
Our systematic review was mainly limited by the difficulty of comparing between studies in this
particular research field. This is due to several reasons. Firstly, laboratories are currently each using
their own methods to measure and quantify the various anti- OxLDL antibody levels, since assays that
measure these levels have not yet been standardised or commercialised. As a result, although we used
broad inclusion criteria, anti-OxLDL antibody levels that were reported in the 18 included studies,
could not be directly compared. Secondly, although we focused on healthy populations or patient
with CVD, and excluded patients with additional diseases, such as auto-immune diseases, residual
heterogeneity between the patient populations of the various included studies remain. Finally, most
included studies used (unstandardized) composite endpoints but failed to report the results for each
individual endpoint.
5. Conclusions
Despite the paucity of studies and lack of conclusive data in the literature, this systematic review
has highlighted clear signals of association between anti-oxLDL antibodies and CAD. IgM anti-oxLDL
antibodies appear to indicate protection from more severe CAD and possibly cardiovascular events,
whilst the relationship with IgG is more complex and difficult to elucidate. Further studies, with
well-characterised prospective cohorts, will be important to clarify these associations.
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